Screener
ANI Pharmaceuticals ANIP Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
FAQ
- What is ANI Pharmaceuticals's total liabilities?
- ANI Pharmaceuticals (ANIP) reported total liabilities of $896.9M in Q2 2026.
- How has ANI Pharmaceuticals's total liabilities changed year-over-year?
- ANI Pharmaceuticals's total liabilities increased by 1.8% year-over-year, from $881.39M to $896.9M.
- What is the long-term trend for ANI Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's total liabilities has grown at a 27.6% compound annual growth rate (CAGR), from $265.49M to $899.65M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about ANI Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude